Genespire SRL

Founded in 2020, Genespire SRL operates from Milan, Italy, specializing in gene therapy innovations.Genespire focuses on the development of innovative gene therapies tailored to address genetic diseases in children. Their primary offering includes immune-shielded lentiviral vectors, which deliver therapeutic genes into patient cells while minimizing immune responses that typically hinder treatment effectiveness. These products aim to improve health outcomes for children with genetic disorders and are advancing through clinical development phases.Genespire generates revenue through strategic partnerships with healthcare institutions and pharmaceutical companies engaged in gene therapy innovations. The company’s financial framework is supported by collaboration agreements and research partnerships, which may include milestone payments associated with clinical trials and regulatory approvals, as well as potential licensing agreements for their proprietary technologies. The firm’s flagship offering positions it for transactions that may involve shared revenue models based on future sales of successful treatments. The company plans to expand its product offerings and geographic reach, particularly targeting markets within Europe where genetic diseases are prevalent.

1. Series B

   Sep 25, 2024

   Amount

   $52M

   Investors

   Locked

2. Series A

   Apr 20, 2020

   Amount

   $17M

   Investors

   Locked